The obesity drug landscape
Amycretin entered the most active area of drug development in a generation, competing against approved heavyweights (se…
Where amycretin sits in a crowded field
Amycretin entered the most active area of drug development in a generation, competing against approved heavyweights (semaglutide, tirzepatide) and a wave of investigational multi-hormone drugs (CagriSema, retatrutide, survodutide, and other amylin agonists).
This unit places amycretin honestly on that map: mechanistically distinctive, with promising early numbers, but far behind on the evidence its rivals have accumulated. It is a newcomer with a novel design, not a proven leader.
Key terms
Weight loss, side by side
The first question everyone asks is "how much weight?" Placed against its rivals, amycretin's early subcutaneous number looks competitive to strong, but the comparison is unfair: its figures come from small phase 1 arms, while the others come from large phase 3 trials over longer durations.
A crucial caveat sits under this chart: the bars come from different trials, phases, timepoints, and populations. Amycretin's tall bar is a small phase 1 arm; the others are mature phase 2 and 3 results, some head-to-head against each other. No head-to-head trial exists for amycretin. It looks competitive, but any claim it is "the strongest" wildly outruns the evidence.
AdvancedWhy cross-trial bar charts mislead
Different trials use different populations, durations, dropout handling, and estimands, so their headline numbers are not directly comparable. A small 36-week phase 1 arm and a 72-week phase 3 trial are measuring different things under different conditions. Cross-trial bars are useful for a rough sense of scale but cannot rank drugs. Only a randomized head-to-head trial, which amycretin has never had, can do that.